Study of a new cell therapy for immune-related kidney disease
Part of Heart & circulation, Immune system & allergy, Kidney & urinary, Skin, Women’s health & pregnancy clinical trials.
This trial tests a new cell therapy called GT719 that targets B cells, part of the immune system that attacks the kidneys in several types of autoimmune kidney disease. It is designed for people whose kidney disease has not improved with standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You must have one of these kidney conditions: IgA nephropathy, ANCA-associated vasculitis with kidney involvement, membranous nephropathy, focal segmental glomerulosclerosis (FSGS), minimal change disease, or proliferative glomerulonephritis with monoclonal immunoglobulin deposition (PGNMID).
- Your kidney disease must be considered high-risk, meaning it has not improved with standard treatments or is likely to get worse.
- You need to have B cells (a type of immune cell) in your blood that the study treatment targets.
- You must have adequate kidney, liver, heart, and lung function, and be generally healthy apart from the kidney disease.
- You must not be on dialysis or have received certain treatments like CAR-T therapy or an organ transplant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new immune cell treatment (CAR-T) for people with certain kidney diseases—IgA nephropathy or membranous nephropathy—that have not improved with standard care. The therapy aims to calm the immune system to protect the kidneys.
This study tests an experimental cell therapy (CAR-γδ T cells) for people with certain autoimmune kidney diseases that have not responded to usual treatments. The goal is to see if this therapy is safe and can help control the disease.
This study tests a new immune cell therapy (called STAR-T cells) for two types of autoimmune kidney disease—IgA nephropathy and membranous nephropathy—that haven't responded to usual treatments. The goal is to stop the immune system from attacking the kidneys, which may help reduce protein in urine and preserve kidney function.
This trial tests a new medication for IgA nephropathy, a kidney disease that causes inflammation and protein loss in urine. It aims to see if the drug can safely slow down kidney damage and protect kidney function.
This trial tests an experimental tablet, HSK39297, for people with IgA nephropathy, a kidney disease. It aims to see if the drug is safe and can help reduce protein in the urine, which is a sign of kidney damage.
This trial is testing a new therapy made from your own immune cells (called CAR NK cells) that are designed to fight a type of kidney disease that hasn't responded to standard treatments. It may be an option if you have membranous nephropathy, IgA nephropathy, or ANCA-associated vasculitis and previous treatments have failed.
Hear when a new IgA Nephropathy (IgAN) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.